AGENAGENUS INC同业对比
AGENUS INC 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGEN本股 | $310M#8 | 2.3x#2 | — | 2.7x#1 | 10.4%#4 | 98.7%#2 | -17.7%#2 | — | — | — | 84.9%#3 | — |
| TECX | $387M#2 | — | 1.7x#8 | — | — | -27.9%#9 | — | -33125.9%#12 | -713.5%#5 | — | 17.9%#6 | — |
| CCCC | $395M#1 | — | 1.6x#7 | 11.0x#4 | 1.0%#6 | 0.3%#5 | -320.5%#5 | -42.5%#4 | — | — | 42.7%#5 | — |
| ZURA | $380M#3 | — | 3.7x#11 | — | — | -31.0%#10 | — | -67.6%#7 | — | — | 14.7%#7 | — |
| SRZN | $370M#4 | — | — | 106.5x#8 | -67.4%#8 | -280.8%#14 | -1210.6%#6 | — | — | — | 125.0%#2 | — |
| KYTX | $321M#5 | — | 1.9x#9 | — | — | -26.5%#8 | — | -97.4%#10 | -107.1%#3 | — | -18.0%#9 | — |
| XFOR | $318M#6 | 2.2x#1 | 2.0x#10 | 9.1x#3 | 1273.2%#2 | -111.5%#12 | -247.4%#3 | -50.9%#6 | -582.0%#4 | — | -18.7%#10 | — |
| SCTX | $312M#7 | — | — | — | — | — | — | — | — | — | — | — |
| EIKN | $304M#9 | — | 0.7x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| IPSC | $299M#10 | — | 1.3x#4 | 2.7x#2 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#3 | -9.3%#1 | — | 189.4%#1 | — |
| SABS | $293M#11 | 13.4x#3 | 1.4x#5 | — | -100.0%#9 | 138.9%#1 | — | 6.2%#1 | — | — | -0.8%#8 | — |
| OCGN | $274M#12 | — | — | 62.1x#7 | 8.8%#5 | -25.9%#7 | -1425.7%#7 | — | — | — | -43.3%#12 | — |
| LXEO | $258M#14 | — | 1.1x#2 | 393.9x#9 | — | -1.7%#6 | -16706.0%#9 | -42.5%#5 | — | — | -62.4%#14 | — |
| LCTX | $264M#13 | — | 4.3x#12 | 18.2x#5 | 53.2%#3 | -241.4%#13 | -251.6%#4 | -104.3%#11 | — | — | -42.4%#11 | — |
| CABA | $248M#15 | — | 1.2x#3 | — | — | -44.9%#11 | — | -79.7%#8 | — | — | -45.9%#13 | — |
| FATE | $244M#16 | — | 1.6x#6 | 36.7x#6 | -51.2%#7 | 26.8%#4 | -2222.4%#8 | -88.8%#9 | -102.3%#2 | — | 70.3%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议